Piper Sandler Maintains Overweight on Revolution Medicines, Raises Price Target to $172

Benzinga Newsdesk www.benzinga.com Positive 78.5%

Neg 0% Neu 0% Pos 78.5%

Piper Sandler analyst Kelsey Goodwin maintains Revolution Medicines (NASDAQ:RVMD) with a Overweight and raises the price target from $120 to $172.